The startup has developed a wearable neuromodulation device in the form of a contact lens that utilizes embedded gold traces to deliver electrical impulses directly to the eye. This device provides a non-invasive therapy for managing elevated intraocular pressure, specifically targeting the treatment of glaucoma.
Funding
$710K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Glaucoma, a leading cause of blindness, is often characterized by elevated intraocular pressure (IOP) that damages the optic nerve. Current treatments primarily involve eye drops or invasive surgeries, which can have compliance issues or significant side effects. There is a need for non-invasive, easily administered therapies to manage IOP and prevent vision loss.
Solution
Bionode is developing a first-in-class eye-tech medical device in the form of a wearable contact lens that provides a non-invasive therapy for managing elevated intraocular pressure (IOP). The contact lens incorporates embedded gold traces to deliver targeted electrical impulses directly to the eye. This electroceutical approach aims to reduce IOP, offering a novel therapeutic intervention for glaucoma management. The device is designed for ease of use and continuous therapy, potentially improving patient compliance and outcomes.
Target Audience
The primary target audience includes individuals diagnosed with glaucoma or at risk of developing glaucoma, as well as ophthalmologists and optometrists seeking innovative, non-invasive treatment options for their patients.
Features
- Wearable contact lens form factor for convenient, non-invasive IOP management
- Embedded gold traces for targeted delivery of electrical impulses to the eye
- Electroceutical mechanism of action to reduce intraocular pressure
- Designed for continuous therapy and improved patient compliance